Picard Medical (PMI) Registration Filing summary

Company overview and business model

• Manufactures and sells the only FDA and Health Canada approved total artificial heart (TAH), with over 2,100 implants in 27 countries.

• Focuses on expanding indications for use (bridge to transplant, bridge to candidacy, long-term use) and developing a fully implantable TAH.

• Operates through SynCardia Systems, with international subsidiaries and a joint venture in China for market expansion.

• Revenue streams include product sales, driver rentals, and training/certification services for transplant centers.

Financial performance and metrics

• 2024 revenues: $4.4M (down 13% from 2023); net loss: $21.1M (up from $15.6M in 2023).

• Gross loss in 2024: $112K; operating expenses: $13.6M; accumulated deficit: $49.8M as of Dec 31, 2024.

• Cash and cash equivalents at year-end 2024: $96K; working capital deficit: $25.5M.

• Significant customer concentration: top three customers accounted for 55% of 2024 revenue.

• Auditor raised substantial doubt about ability to continue as a going concern without additional funding.

Use of proceeds and capital allocation

• Proceeds will fund China joint venture ($2.85M), R&D for fully implantable system (up to $5M), sales/marketing expansion ($1M), and general operations ($4M).

• Additional capital will support inventory, next-generation driver development, and working capital.